1/2
08:16 am
bpmc
Blueprint Medicines Co. (NASDAQ: BPMC) had its "overweight" rating re-affirmed by analysts at Stephens. They now have a $140.00 price target on the stock.
Low
Report
Blueprint Medicines Co. (NASDAQ: BPMC) had its "overweight" rating re-affirmed by analysts at Stephens. They now have a $140.00 price target on the stock.
12/18
08:14 am
bpmc
Blueprint Medicines to Present at the 43rd Annual J.P. Morgan Healthcare Conference [Yahoo! Finance]
Medium
Report
Blueprint Medicines to Present at the 43rd Annual J.P. Morgan Healthcare Conference [Yahoo! Finance]
12/18
08:00 am
bpmc
Blueprint Medicines to Present at the 43rd Annual J.P. Morgan Healthcare Conference
Medium
Report
Blueprint Medicines to Present at the 43rd Annual J.P. Morgan Healthcare Conference
12/11
12:30 pm
bpmc
Blueprint Medicines Co. (NASDAQ: BPMC) had its "buy" rating re-affirmed by analysts at Guggenheim.
Low
Report
Blueprint Medicines Co. (NASDAQ: BPMC) had its "buy" rating re-affirmed by analysts at Guggenheim.
12/9
11:17 am
bpmc
Blueprint Medicines Co. (NASDAQ: BPMC) had its "market outperform" rating re-affirmed by analysts at JMP Securities. They now have a $125.00 price target on the stock.
Low
Report
Blueprint Medicines Co. (NASDAQ: BPMC) had its "market outperform" rating re-affirmed by analysts at JMP Securities. They now have a $125.00 price target on the stock.
12/7
12:35 pm
bpmc
Blueprint Medicines' Continued Leadership in Redefining the Standard of Care in Systemic Mastocytosis Highlighted at 2024 ASH Annual Meeting [Yahoo! Finance]
Low
Report
Blueprint Medicines' Continued Leadership in Redefining the Standard of Care in Systemic Mastocytosis Highlighted at 2024 ASH Annual Meeting [Yahoo! Finance]
12/7
12:30 pm
bpmc
Blueprint Medicines' Continued Leadership in Redefining the Standard of Care in Systemic Mastocytosis Highlighted at 2024 ASH Annual Meeting
Low
Report
Blueprint Medicines' Continued Leadership in Redefining the Standard of Care in Systemic Mastocytosis Highlighted at 2024 ASH Annual Meeting
12/3
06:03 am
bpmc
30 Under 30 Healthcare 2025: Advancing AI, Delivering Care And Creating New Therapies [Forbes]
Low
Report
30 Under 30 Healthcare 2025: Advancing AI, Delivering Care And Creating New Therapies [Forbes]
11/29
01:00 pm
bpmc
Blueprint Medicines (BPMC) Up 8.7% Since Last Earnings Report: Can It Continue? [Yahoo! Finance]
Neutral
Report
Blueprint Medicines (BPMC) Up 8.7% Since Last Earnings Report: Can It Continue? [Yahoo! Finance]
11/25
08:10 am
bpmc
Recludix Pharma to Participate in Two Investor Conferences in December [Yahoo! Finance]
Low
Report
Recludix Pharma to Participate in Two Investor Conferences in December [Yahoo! Finance]
11/18
01:35 pm
bpmc
Blueprint Medicines Co. (NASDAQ: BPMC) had its "market outperform" rating re-affirmed by analysts at JMP Securities. They now have a $125.00 price target on the stock.
Low
Report
Blueprint Medicines Co. (NASDAQ: BPMC) had its "market outperform" rating re-affirmed by analysts at JMP Securities. They now have a $125.00 price target on the stock.
11/15
08:04 am
bpmc
Blueprint Medicines Co. (NASDAQ: BPMC) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $135.00 price target on the stock.
Medium
Report
Blueprint Medicines Co. (NASDAQ: BPMC) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $135.00 price target on the stock.
11/15
08:04 am
bpmc
Blueprint Medicines Co. (NASDAQ: BPMC) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $135.00 price target on the stock.
Medium
Report
Blueprint Medicines Co. (NASDAQ: BPMC) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $135.00 price target on the stock.
11/14
06:29 pm
bpmc
Blueprint Medicines Co. (NASDAQ: BPMC) had its "outperform" rating re-affirmed by analysts at Wedbush. They now have a $135.00 price target on the stock.
Medium
Report
Blueprint Medicines Co. (NASDAQ: BPMC) had its "outperform" rating re-affirmed by analysts at Wedbush. They now have a $135.00 price target on the stock.
11/14
10:14 am
bpmc
Recludix Pharma to Present Data Demonstrating its Oral STAT3 Inhibitor has Differentiated Efficacy and Safety as Compared to JAK/TYK2 Inhibition in In Vivo Models of Inflammatory Arthritis [Yahoo! Finance]
Low
Report
Recludix Pharma to Present Data Demonstrating its Oral STAT3 Inhibitor has Differentiated Efficacy and Safety as Compared to JAK/TYK2 Inhibition in In Vivo Models of Inflammatory Arthritis [Yahoo! Finance]
11/14
07:35 am
bpmc
Blueprint Medicines Co. (NASDAQ: BPMC) is now covered by analysts at JPMorgan Chase & Co.. They set an "overweight" rating and a $126.00 price target on the stock.
Medium
Report
Blueprint Medicines Co. (NASDAQ: BPMC) is now covered by analysts at JPMorgan Chase & Co.. They set an "overweight" rating and a $126.00 price target on the stock.
11/2
10:36 am
bpmc
Analysts Have Made A Financial Statement On Blueprint Medicines Corporation's (NASDAQ:BPMC) Third-Quarter Report [Yahoo! Finance]
Low
Report
Analysts Have Made A Financial Statement On Blueprint Medicines Corporation's (NASDAQ:BPMC) Third-Quarter Report [Yahoo! Finance]
11/1
09:29 am
bpmc
Blueprint Medicines Third Quarter 2024 Earnings: EPS Beats Expectations [Yahoo! Finance]
Low
Report
Blueprint Medicines Third Quarter 2024 Earnings: EPS Beats Expectations [Yahoo! Finance]
10/31
11:05 pm
bpmc
Blueprint Medicines Co. (NASDAQ: BPMC) was downgraded by analysts at StockNews.com from a "hold" rating to a "sell" rating.
Low
Report
Blueprint Medicines Co. (NASDAQ: BPMC) was downgraded by analysts at StockNews.com from a "hold" rating to a "sell" rating.
10/31
03:47 pm
bpmc
Blueprint Medicines Co. (NASDAQ: BPMC) had its price target lowered by analysts at Wells Fargo & Company from $153.00 to $151.00. They now have an "overweight" rating on the stock.
Low
Report
Blueprint Medicines Co. (NASDAQ: BPMC) had its price target lowered by analysts at Wells Fargo & Company from $153.00 to $151.00. They now have an "overweight" rating on the stock.
10/31
08:35 am
bpmc
Blueprint Medicines Co. (NASDAQ: BPMC) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $135.00 price target on the stock.
Medium
Report
Blueprint Medicines Co. (NASDAQ: BPMC) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $135.00 price target on the stock.
10/30
02:32 pm
bpmc
Blueprint Medicines Corporation (BPMC) Q3 2024 Earnings Call Transcript [Seeking Alpha]
Low
Report
Blueprint Medicines Corporation (BPMC) Q3 2024 Earnings Call Transcript [Seeking Alpha]
10/30
08:00 am
bpmc
Blueprint Medicines Co. (NASDAQ: BPMC) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $133.00 price target on the stock.
Medium
Report
Blueprint Medicines Co. (NASDAQ: BPMC) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $133.00 price target on the stock.
10/30
07:00 am
bpmc
Blueprint Medicines Reports Third Quarter 2024 Results and Raises AYVAKIT®/AYVAKYT® (avapritinib) Full Year Revenue Guidance
Medium
Report
Blueprint Medicines Reports Third Quarter 2024 Results and Raises AYVAKIT®/AYVAKYT® (avapritinib) Full Year Revenue Guidance
10/27
10:02 am
bpmc
Blueprint Medicines Corporation (NASDAQ:BPMC): Are Analysts Optimistic? [Yahoo! Finance]
Low
Report
Blueprint Medicines Corporation (NASDAQ:BPMC): Are Analysts Optimistic? [Yahoo! Finance]